BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer

BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer

Submitted by admin on February 10, 2021 - 12:09am
Source: 
PM Live
News Tags: 
Bristol Myers Squibb
Exelixix
Opdivo
Cabometyx
kidney cancer
Headline: 
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer
snippet: 

Bristol Myers Squibb (BMS) and Exelixis have revealed new analyses from a phase 3 study of their Opdivo and Cabometyx combination in kidney cancer.

Do Not Allow Advertisers to Use My Personal information